Public market insider buying at Knight Therapeutics (GUD)

Public market insider buying at Knight Therapeutics (T:GUD)

Updated Friday Apr 12, 2019 03:04 AM EDT
Jonathan Goodman, CEO, Director and 10% Holder, acquired 16,200 Common Shares on a direct ownership basis at prices ranging from $7.350 to $7.420 between April 4th, 2019 and April 10th, 2019. This represents a $119,808 investment into the company's shares and an account share holdings change of 3.7%.

Knight Therapeutics is in the Pharmaceuticals Sub Industry Group under the Healthcare Sector.

Knight Therapeutics Inc is a Canada-based pharmaceutical company. The Company is engaged in developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products, consumer health products and medical devices in Canada and select international markets. It finances other life sciences companies in Canada and internationally. Its prescription pharmaceuticals and medical devices in various stages of development include Impavido, AzaSite, ATryn, Photofrin, ILUVIEN, TULSA-PRO, PROBUPHINE, Advaxis Family of Products, Ember Family of Products, NeurAxon Family of Products, Antibe Family of Products, Blood Factor Products and VEWS Vascular Early Warning System. In addition, the Company also has a portfolio of branded consumer health products, including Neuragen, Flat Tummy Tea, FOCUSFactor, FLEXISEQ, SEQuaderma, HandMD, UrgentRx, Laboratoire Dr. Renaud, Premiology and Pro-Derm.

GUD Insider Holdings Chart

Issuer details as of Apr 12, 2019 3:04 ET

Latest Price
7.39
1 Day Change
-0.54%
52 Week High
8.81
52 Week Low
7.27
QMV ($Mils)
1,055,733,124


Top